Active Recombinant Mouse Fibroblast Growth Factor Receptor 3, Fc-tagged

• Cat.No.: Fgfr3-536M
• Product Overview: Recombinant Mouse Fgfr3protein was expressed in Murine myeloma cell line with the Fc part of humanIgG1 Pro100-Lys330 (C-terminus) and Ala33-Tyr367 (N-terminus).

Specification

• Cat. No.: Fgfr3-536M
• Description: Fibroblast growthfactors (FGFs) comprise a family of at least eighteen structurally relatedproteins that are involved in a multitude of physiological and pathologicalcellular processes, including cell growth, differentiation, angiogenesis,wound healing and tumorgenesis. The biological activities of the FGFs aremediated by a family of type I transmembrane tyrosine kinases which undergodimerization and autophosphorylation after ligand binding. Four distinctgenes encoding closely related FGF receptors, FGF R1-4, are known.
• Source: Mammalian cells
• Form: Lyophilized from a0.2 μm filtered solution in PBS.
• N-terminalSequence: Ala33
• Molecular Weight: 63 kDa
• Activity: Measuredby its ability to inhibit FGF acidicdependent proliferation of NR6R-3T3 mousefibroblasts. The ED50 for this effect is typically 2-6 ng/mL.
• Endotoxin Level: <1.0 EUper 1 μg of the protein by the LAL method.
• SDS-PAGE: 100-110kDa, reducing conditions
• Purity: >90%,by SDS-PAGE under reducing conditions and visualized by silver stain.
• Reconstitution: Reconstituteat 100 μg/mL in sterile PBS
• Storage: Use a manualdefrost freezer and avoid repeated freezethaw cycles. 12 months from date of receipt,-20 to -70°C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution.3 months, -20 to -70°C under sterile conditions after reconstitution.

Gene Information

• Gene Name: Fgfr3 fibroblast growth factorreceptor 3 [ Mus musculus ]
• Official Symbol: Fgfr3
• Synonyms: Fgfr3;fibroblast growth factor receptor 3; FR3; Mfr3; sam3; CD333; Flg-2; HBGFR;Fgfr-3; fibroblast growth factor receptor 3; heparin-binding growth factorreceptor; EC 2.7.10.1; mCG_16331
• Gene ID: 14184
• mRNA Refseq: NM_001163215
• Protein Refseq: NP_001156687
• UniProt ID: Q61851
• Chromosome Location: 5 B; 5 20.0 cM
• Pathway: Downstream signalingof activated FGFR; ESC Pluripotency Pathways; FGFR ligand binding andactivation; IRS-mediated signalling; IRS-related events; Insulin receptorsignalling cascade; MAPK signaling pathway; PI-3K cascade; Pathways incancer; Phospholipase C-mediated cascade; Regulation of Actin Cytoskeleton; Signalingby FGFR; Signaling by Insulin receptor; Bladder cancer; EndochondralOssification
• Function: ATP binding;fibroblast growth factor binding; fibroblast growth factor-activated receptoractivity; kinase activity; nucleotide binding; protein binding; proteintyrosine kinase activity; receptor activity; transferase activity;transmembrane receptor protein tyrosine kinase activity

Reviews

01/13/2020

Researchers who have utilized FGFR3 protein praise its exceptional performance and reliability in their experiments.

03/26/2018

Its high sensitivity enables the identification of low abundance targets, making it highly valuable in immunological research.

08/29/2017

Its stability and compatibility with electron microscopy techniques make it an ideal candidate for studying protein structures at high resolution.

Q&As

How does FGFR3 testing assist in personalized medicine approaches?

FGFR3 testing helps identify specific genetic mutations, allowing for personalized treatment plans tailored to an individual's genetic profile.

Is FGFR3 testing routinely conducted in cancer diagnosis?

FGFR3 testing is becoming more common, especially in cases where specific cancers associated with FGFR3 mutations are suspected.

Can FGFR3 be a prognostic marker in cancer?

Yes, FGFR3 status can serve as a prognostic marker, influencing the prediction of disease progression and patient outcomes.

Are there targeted therapies based on FGFR3 in cancer treatment?

Yes, FGFR3-targeted therapies are being developed for cancer treatment, particularly for patients with FGFR3 mutations.

How is FGFR3 targeted in cancer therapy?

FGFR3-targeted therapies may involve small molecule inhibitors or monoclonal antibodies that specifically block the activity of mutated FGFR3.